Latest news for VitaSpring Biomedical (OTC:VSBC) Stock

VitaSpring Biomedical Co Ltd is a start-up business company. The company's objective is to develop new drugs in cell medicine. The company also plans to produce X.MSC cytopharmaceuticals.

VITASPRING BIOMEDICAL CO by VitaSpring Biomedical Co. Ltd.

VitaSpring Biomedical Co Ltd

<p>Baird  analyst Timothy Wojs   maintains Stanley Black &amp; Decker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) with a Neutral and raises the price target from $80 to $94.</p>


News

Price Target

Analyst Ratings

Baird Maintains Neutral on Stanley Black & Decker, Raises Price Target to $94

<p>Wells Fargo  analyst Andrew Bauch   maintains Remitly Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELY#NASDAQ">RELY</a>) with a Underweight and lowers the price target from $15 to $13.</p>


RELY

Wells Fargo Maintains Underweight on Remitly Global, Lowers Price Target to $13

<p>Wells Fargo  analyst Andrew Bauch   maintains PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) with a Equal-Weight and raises the price target from $65 to $70.</p>


PYPL

Wells Fargo Maintains Equal-Weight on PayPal Holdings, Raises Price Target to $70

<p>Deep-pocketed investors have adopted a bullish approach towards DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DASH usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for DoorDash. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 55% leaning bullish and 33% bearish. Among these notable options, 3 are puts, totaling $406,928, and 6 are calls, amounting to $255,250.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $90.0 and $127.0 for DoorDash, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for DoorDash's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of DoorDash's whale activity within a strike price range from $90.0 to $127.0 in the last 30 days. </p>
<h3>DoorDash Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722442575_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DASH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$6.7</td>
<td>$6.55</td>
<td>$6.6</td>
<td>$100.00</td>
<td>$297.0K</td>
<td>566</td>
<td>581</td>
</tr>
<tr>
<td>DASH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/02/24</td>
<td>$1.05</td>
<td>$1.02</td>
<td>$1.05</td>
<td>$127.00</td>
<td>$91.3K</td>
<td>60</td>
<td>2.0K</td>
</tr>
<tr>
<td>DASH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$6.65</td>
<td>$6.35</td>
<td>$6.4</td>
<td>$90.00</td>
<td>$67.2K</td>
<td>1.6K</td>
<td>105</td>
</tr>
<tr>
<td>DASH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$6.65</td>
<td>$6.45</td>
<td>$6.54</td>
<td>$100.00</td>
<td>$42.7K</td>
<td>566</td>
<td>131</td>
</tr>
<tr>
<td>DASH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/02/24</td>
<td>$1.26</td>
<td>$1.25</td>
<td>$1.26</td>
<td>$127.00</td>
<td>$36.2K</td>
<td>60</td>
<td>290</td>
</tr>
</tbody>
</table>
</p>
<h3>About DoorDash</h3>
<p>Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the US. Through the acquisition of Wolt in 2022, the firm also provides this service in Europe. DoorDash provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers.</p>
<h3>DoorDash's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 1,728,681, the DASH's price is up by 2.64%, now at $110.03. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 1 days.</li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for DoorDash with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

DASH

Market Whales and Their Recent Bets on DASH Options

<p>Baird  analyst Colin Sebastian   maintains PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) with a Outperform and raises the price target from $77 to $80.</p>


Baird Maintains Outperform on PayPal Holdings, Raises Price Target to $80

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Pfizer</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PFE, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 18 options trades for <strong>Pfizer</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 38% bullish and 55%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $32,480, and 17, calls, for a total amount of $785,136.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $17.5 to $35.0 for Pfizer over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Pfizer's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Pfizer's whale trades within a strike price range from $17.5 to $35.0 in the last 30 days. </p>
<h3>Pfizer Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722442570_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/02/24</td>
<td>$0.47</td>
<td>$0.45</td>
<td>$0.45</td>
<td>$30.50</td>
<td>$135.0K</td>
<td>10.4K</td>
<td>1.4K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$2.5</td>
<td>$2.32</td>
<td>$2.4</td>
<td>$35.00</td>
<td>$120.0K</td>
<td>28.3K</td>
<td>632</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/02/24</td>
<td>$1.0</td>
<td>$0.97</td>
<td>$1.0</td>
<td>$30.00</td>
<td>$50.0K</td>
<td>10.5K</td>
<td>2.1K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$4.95</td>
<td>$4.85</td>
<td>$4.95</td>
<td>$26.00</td>
<td>$49.5K</td>
<td>733</td>
<td>100</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.06</td>
<td>$2.03</td>
<td>$2.06</td>
<td>$31.00</td>
<td>$39.9K</td>
<td>4.2K</td>
<td>330</td>
</tr>
</tbody>
</table>
</p>
<h3>About Pfizer</h3>
<p>Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.</p>
<h3>Current Position of Pfizer</h3>
<ul>
<li>With a volume of 15,092,694, the price of PFE is down -1.31% at $30.98. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 90 days.</li>
</ul>
<h3>Professional Analyst Ratings for Pfizer</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $36.2.</p>
<ul>
<li>An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $45. </li>
<li>Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on Pfizer with a target price of $31. </li>
<li>Consistent in their evaluation, an analyst from Wells Fargo keeps a Equal-Weight rating on Pfizer with a target price of $30. </li>
<li>An analyst from Barclays has decided to maintain their Equal-Weight rating on Pfizer, which currently sits at a price target of $30. </li>
<li>Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $45.</li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Pfizer options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Pfizer's Options Frenzy: What You Need to Know

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>McKesson</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MCK, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 10 uncommon options trades for McKesson.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 50% bullish and 40%, bearish.</p>
<p>Out of all of the special options we uncovered, 7 are puts, for a total amount of $362,632, and 3 are calls, for a total amount of $150,643.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $570.0 and $640.0 for McKesson, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for McKesson's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of McKesson's whale trades within a strike price range from $570.0 to $640.0 in the last 30 days. </p>
<h3>McKesson Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722442565_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$12.3</td>
<td>$11.0</td>
<td>$11.8</td>
<td>$570.00</td>
<td>$128.6K</td>
<td style="text-align: right;">378</td>
<td style="text-align: right;">225</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$102.4</td>
<td>$95.3</td>
<td>$101.27</td>
<td>$600.00</td>
<td>$80.7K</td>
<td style="text-align: right;">243</td>
<td style="text-align: right;">8</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$12.2</td>
<td>$10.2</td>
<td>$12.2</td>
<td>$570.00</td>
<td>$48.8K</td>
<td style="text-align: right;">378</td>
<td style="text-align: right;">60</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$16.4</td>
<td>$16.0</td>
<td>$16.11</td>
<td>$610.00</td>
<td>$48.3K</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">40</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/02/24</td>
<td>$4.5</td>
<td>$3.9</td>
<td>$4.5</td>
<td>$610.00</td>
<td>$45.0K</td>
<td style="text-align: right;">202</td>
<td style="text-align: right;">100</td>
</tr>
</tbody>
</table>
</p>
<h3>About McKesson</h3>
<p>McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the us pharmaceutical wholesale industry. Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.</p>
<p>Having examined the options trading patterns of McKesson, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>McKesson's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 214,104, the MCK's price is up by 1.33%, now at $617.82. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 7 days.</li>
</ul>
<h3>What The Experts Say On McKesson</h3>
<p>3 market experts have recently issued ratings for this stock, with a consensus target price of $674.6666666666666.</p>
<ul>
<li>Consistent in their evaluation, an analyst from Baird keeps a Outperform rating on McKesson with a target price of $694. </li>
<li>An analyst from Citigroup persists with their Buy rating on McKesson, maintaining a target price of $670. </li>
<li>Consistent in their evaluation, an analyst from Evercore ISI Group keeps a Outperform rating on McKesson with a target price of $660. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for McKesson, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


McKesson's Options Frenzy: What You Need to Know

<p>Wells Fargo  analyst Andrew Bauch   maintains Lightspeed Commerce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSPD#NYSE">LSPD</a>) with a Equal-Weight and lowers the price target from $17 to $15.</p>


LSPD

Wells Fargo Maintains Equal-Weight on Lightspeed Commerce, Lowers Price Target to $15

<p>Baird  analyst Rob Oliver   maintains Pros Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRO#NYSE">PRO</a>) with a Outperform and lowers the price target from $45 to $35.</p>


Baird Maintains Outperform on Pros Holdings, Lowers Price Target to $35

<p>Wedbush  analyst David Chiaverini   maintains Axos Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AX#NYSE">AX</a>) with a Neutral and raises the price target from $60 to $80.</p>


Wedbush Maintains Neutral on Axos Financial, Raises Price Target to $80

<p>Wells Fargo  analyst Eric Luebchow   maintains American Tower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) with a Overweight and raises the price target from $225 to $245.</p>


Wells Fargo Maintains Overweight on American Tower, Raises Price Target to $245

WIIM

Northern Oil and Gas shares are trading higher after the company reported better-than-expected Q2 sales results.

<p>Baird  analyst Colin Sebastian   maintains Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) with a Outperform and lowers the price target from $44 to $41.</p>


PINS

Baird Maintains Outperform on Pinterest, Lowers Price Target to $41

<p>Wedbush  analyst David Chiaverini   maintains LendingClub (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) with a Outperform and raises the price target from $11 to $14.</p>


Wedbush Maintains Outperform on LendingClub, Raises Price Target to $14

<p>Wells Fargo  analyst Joseph O'Dea   maintains Stanley Black &amp; Decker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) with a Equal-Weight and raises the price target from $85 to $110.</p>


Wells Fargo Maintains Equal-Weight on Stanley Black & Decker, Raises Price Target to $110

AutoNation shares are trading higher. The company reported Q2 financial results.

<p>Baird  analyst David Rescott   maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Outperform and lowers the price target from $231 to $180.</p>


Baird Maintains Outperform on Penumbra, Lowers Price Target to $180

<p>Wells Fargo  analyst Joseph O'Dea   maintains Illinois Tool Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>) with a Underweight and raises the price target from $230 to $236.</p>


Wells Fargo Maintains Underweight on Illinois Tool Works, Raises Price Target to $236

<p>Wedbush  analyst Richard Anderson   maintains Safehold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAFE#NYSE">SAFE</a>) with a Neutral and raises the price target from $20 to $25.</p>


SAFE

Wedbush Maintains Neutral on Safehold, Raises Price Target to $25

<p>Wells Fargo  analyst Joseph O'Dea   maintains Hubbell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>) with a Equal-Weight and raises the price target from $397 to $400.</p>


The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

VitaSpring Biomedical

News

Latest news for VitaSpring Biomedical (OTC:VSBC) Stock